Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)‘s stock had its “buy” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Thursday. They presently have a $33.00 target price on the biopharmaceutical company’s stock. Wedbush’s target price would suggest a potential upside of 119.56% from the company’s current price.
A number of other equities analysts also recently commented on LXRX. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 6th. Citigroup Inc. began coverage on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 2nd. They issued a “buy” rating and a $21.00 price target for the company. Stifel Nicolaus increased their price target on shares of Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a report on Friday, August 5th. Needham & Company LLC reiterated a “buy” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, August 11th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Friday, September 9th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $23.86.
Lexicon Pharmaceuticals (NASDAQ:LXRX) opened at 15.03 on Thursday. The stock’s market capitalization is $1.56 billion. Lexicon Pharmaceuticals has a 52 week low of $7.65 and a 52 week high of $19.62. The firm’s 50-day moving average is $17.70 and its 200-day moving average is $15.22.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.04. The company earned $20.10 million during the quarter, compared to the consensus estimate of $12.36 million. Lexicon Pharmaceuticals had a negative net margin of 13.42% and a negative return on equity of 9.03%. Lexicon Pharmaceuticals’s quarterly revenue was up 5186.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.27) EPS. On average, equities research analysts predict that Lexicon Pharmaceuticals will post ($1.59) EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Quantbot Technologies LP boosted its stake in shares of Lexicon Pharmaceuticals by 12.3% in the second quarter. Quantbot Technologies LP now owns 13,999 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,529 shares during the last quarter. California State Teachers Retirement System boosted its stake in Lexicon Pharmaceuticals by 0.7% in the second quarter. California State Teachers Retirement System now owns 88,627 shares of the biopharmaceutical company’s stock valued at $1,272,000 after buying an additional 602 shares in the last quarter. Capital Fund Management S.A. purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $283,000. American Century Companies Inc. purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $2,194,000. Finally, Falcon Point Capital LLC boosted its stake in Lexicon Pharmaceuticals by 3.5% in the second quarter. Falcon Point Capital LLC now owns 287,809 shares of the biopharmaceutical company’s stock valued at $4,130,000 after buying an additional 9,816 shares in the last quarter.
About Lexicon Pharmaceuticals